Summary
- HIMS stock jumps 23% following Q1 earnings beat and raised FY2025 guidance.
- Subscriber base grew to 2.2 million active users, up 29% YoY.
- Telehealth growth, skincare product demand, and pharmacy fulfillment drove performance.
- Analysts are turning bullish as Hims & Hers expands into weight loss and men’s longevity care.
HIMS Stock Soars After Blowout Q1, Surging User Growth
Hims & Hers Health Inc. (NYSE: HIMS) delivered one of the strongest earnings surprises of the week, sending its shares up 23% in intraday trading on April 30. The company announced that its active subscriber count now sits at 2.2 million, a 29% increase from a year ago.
Revenue for Q1 2025 came in at $299 million, exceeding expectations by nearly $14 million. The company also raised its full-year revenue forecast to $1.28–$1.34 billion, citing strong tailwinds in men’s health, dermatology, and new initiatives in weight management.
What’s Fueling the HIMS Rally?
1. Subscription Growth
Hims & Hers continues to scale its direct-to-consumer subscription model, with strong retention rates and average order values climbing above $70/month. CEO Andrew Dudum noted that recurring revenue now makes up over 89% of total sales.
2. Expansion into Weight Loss and GLP-1 Telehealth
The company recently entered the weight management sector, offering GLP-1 prescriptions via telehealth for eligible patients — a move that mirrors growth seen in companies like Ro and Teladoc.
3. Pharmacy & Fulfillment Efficiency
With vertical integration of its pharmacy and fulfillment network, Hims is reducing cost per shipment and improving order delivery timelines — a key edge in consumer healthcare logistics.
Analyst Reactions
Wall Street analysts were quick to respond to the Q1 beat:
- Goldman Sachs upgraded HIMS to “Buy,” citing accelerating operating leverage and scalable digital infrastructure.
- JP Morgan raised its price target from $15 to $21, calling the company “a category-defining D2C healthtech brand.”
- Needham maintained a “Hold” rating, cautioning that increased competition in telemedicine could compress margins later this year.
Competitive Landscape and Growth Outlook
Hims & Hers is currently fending off competition from Ro, Amazon Clinic, and traditional pharmacy chains expanding digital services. However, its strong brand, personalized treatment plans, and data-driven product iteration keep it well-positioned.
Looking forward, HIMS plans to:
- Expand internationally, starting with Canada and the U.K.
- Launch men’s longevity and preventive health verticals
- Add AI-driven symptom screening and remote diagnostics tools
If executed correctly, these efforts could propel subscriber counts toward the 3 million mark by early 2026, analysts suggest.
Final Thoughts
With record subscriber growth, new high-demand verticals like weight loss and longevity care, and a clean balance sheet, Hims & Hers is no longer just a startup success story — it’s a scalable digital health platform.
The Q1 earnings report proves that HIMS has not only achieved profitability but is also building a high-margin, recurring revenue machine in one of the most sought-after sectors of the next decade.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.
Since 2023, Yoshi Ae has combined storytelling and community insight as a PR writer, creating content that resonates across platforms like X and Discord. From press releases to narrative campaigns, Yoshi bridges brand messaging with real-time community engagement.
